Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer

被引：0
|
作者：
Sarfaty, Michal
Hall, Peter
Chan, Kelvin K.
Virik, Kiran
Leshno, Moshe
Gordon, Noa
Moore, Assaf
Neiman, Victoria
Rosenbaum, Eli
Goldstein, Daniel A.
机构：
[1] Davidoff Canc Ctr, Petah Tiqwa, Israel
[2] Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland
[3] Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Queens Univ Canc Ctr SE Ontario, Kingston, ON, Canada
[5] Tel Aviv Univ, Coller Sch Management, Tel Aviv, Israel
[6] Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
472
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    [J]. EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [2] Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2019, 202 (06): : 1095 - 1096
  • [3] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [4] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    [J]. JAMA NETWORK OPEN, 2021, 4 (01)
  • [5] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS A SECOND-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN THE UNITED STATES
    Chen, N. C.
    McQueen, R.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [6] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [7] Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
    Lam, Simon W.
    Wai, Maya
    Lau, Jessica E.
    McNamara, Michael
    Earl, Marc
    Udeh, Belinda
    [J]. PHARMACOTHERAPY, 2017, 37 (01): : 94 - 103
  • [8] Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
    Srivastava, Tushar
    Prabhu, Vimalanand S.
    Li, Haojie
    Xu, Ruifeng
    Zarabi, Natalie
    Zhong, Yichen
    Pellissier, James M.
    Perini, Rodolfo F.
    de Wit, Ronald
    Mamtani, Ronac
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 663 - 670
  • [9] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    K. Zhou
    F. Wen
    P. Zhang
    J. Zhou
    H. Chen
    H. Zheng
    Y. Yang
    Q. Li
    [J]. Clinical and Translational Oncology, 2017, 19 : 1117 - 1124
  • [10] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
12345